Raising Health Building AI Foundation Models for Molecular Design
17 snips
Jan 8, 2026 
Jeremy Wohlwend and Gabriele Corso, co-founders of Boltz, delve into the transformative power of AI in molecular biology. They discuss Boltz’s mission to create open-source models that revolutionize biomolecular interaction and drug discovery. The conversation highlights breakthroughs post-AlphaFold, the rapid adoption of Boltz models by the pharma sector, and the launch of Boltz Lab—designed to streamline protein and small-molecule design in scientific workflows. They envision a future where AI accelerates iteration and enhances the drug discovery process.
AI Snips
Chapters
Transcript
Episode notes
Productize Models For Real Labs
- Move beyond GitHub: build products that let noncomputational scientists use the models in workflows.
- Invest in engineering, security, and enterprise support to scale real-world impact.
Treat Discovery Like Infrastructure
- Treat molecule discovery as heavy infrastructure: provision large compute and parallelize workflows to shorten turnaround.
- Build engineering teams focused on scaling inference and search across molecular space.
PBC Status Embeds The Mission
- Incorporating a public benefit charter locks the mission to widen access to frontier biomolecular AI.
- Boltz sees the PBC status as a permanent reminder aligning commercial goals with open accessibility.